NeuroBo Pharmaceuticals Inc. (NRBO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NRBO Stock Price Chart Interactive Chart >
NRBO Price/Volume Stats
| Current price | $0.43 | 52-week high | $6.57 |
| Prev. close | $0.43 | 52-week low | $0.38 |
| Day low | $0.43 | Volume | 94,300 |
| Day high | $0.45 | Avg. volume | 457,489 |
| 50-day MA | $0.72 | Dividend yield | N/A |
| 200-day MA | $1.65 | Market Cap | 11.50M |
NeuroBo Pharmaceuticals Inc. (NRBO) Company Bio
NeuroBo Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals conducts business in the United States.
Latest NRBO News From Around the Web
Below are the latest news stories about NeuroBo Pharmaceuticals Inc that investors may wish to consider to help them evaluate NRBO as an investment opportunity.
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of DirectorsNeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022. Mr. Strickland will serve as Chair of the Company's Audit Committee. |
10 Low-Float Penny Stocks for Steel-Gutted InvestorsIf you’re willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, trader! |
NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial ResultsNeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2021. |
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive OfficerNeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced that the Company has appointed Gil Price, M.D. as President and Chief Executive Officer. Dr. Price will replace Dr. Richard J. Kang, Ph.D., who is stepping down later this month to pursue other opportunities, while remaining on the Board of Directors. In the inte |
NRBO Price Returns
| 1-mo | -26.14% |
| 3-mo | -44.55% |
| 6-mo | -75.84% |
| 1-year | -85.27% |
| 3-year | -98.30% |
| 5-year | -99.84% |
| YTD | -64.75% |
| 2021 | -76.76% |
| 2020 | -40.00% |
| 2019 | -56.79% |
| 2018 | -89.80% |
| 2017 | 1.34% |
Loading social stream, please wait...